The Human Vaccines Project recently welcomed its latest member, MedImmune, to help speed the research and development process for vaccines as well as immunotherapies that are used for cancer and infectious diseases.
The Human Vaccines Project is incubated at the International AIDS Vaccine Initiative (IAVI). The purpose of the project is to create a new, ambitious public-private partnership that will change the future of worldwide disease treatment and prevention. The project wants to solve the primary scientific obstacles that are currently standing in the way of research and development for novel immunotherapies and vaccines.
“The human immune system is one of the most potent tools medicine has in the fight against disease,” Ronald Herbst, MedImmune’s vice president of oncology research and development, said. “We look forward to sharing our biologics expertise in immunology and infectious disease, while working with some of the key leaders in this area to help advance drug and vaccine development against a wide range of diseases.”
The project has received support from 36 top vaccine scientists and unites similar leading academic research centers, nonprofit organizations, governments and industry research and development efforts.
“Engagement with leading industry partners such as MedImmune is central to achieving the Project’s ultimate goal of revolutionizing vaccine and immunotherapy development to create a new paradigm for global disease prevention,” Wayne C. Koff, IAVI chief scientific officer and co-founder of the Human Vaccines Project, said.
